Please login to the form below

Not currently logged in
Email:
Password:

Editas Medicine adds to board of directors

Alnylam Pharmaceuticals’ Dr Akshay Vaishnaw joins

Editas Medicine Dr Akshay VaishnawCambridge, Massachusetts-based Editas Medicine has appointed Dr Akshay Vaishnaw to its board of directors.

Dr Vaishnaw brings over 30 years of pharmaceuticals experience to the genome editing company, and currently serves as both executive vice president of research and development and chief medical officer at Alnylam Pharmaceuticals.

Prior to joining Alnylam in 2006, he worked in medical research at Biogen and held roles of increasing responsibility before becoming senior director of medical research.

Katrine Bosley, Editas Medicine's president and chief executive officer, said: “I am delighted to welcome Akshay to our board of directors.

“He has extensive clinical development experience, a passion for scientific excellence, and achieved significant accomplishments as part of the leadership team that has built Alnylam.

“We believe Akshay's perspective and advice will be invaluable as we continue to advance the organisation and drive innovative new medicines to treat genetic diseases.”

2nd August 2016

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
BOLDSCIENCE

We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics